ROS1 REARRANGEMENT

ROS1是一种受体酪氨酸激酶，经常在几种癌症类型中形成基因融合。大约2%的非小细胞肺癌患者有ROS1基因融合。一些融合伙伴被描述为具有恒定的ROS1断点，维持激酶域（Solomon B，2015）。在病例研究和回顾性分析之后，一项1期研究的扩展队列研究显示了环唑替尼在ROS1重组NSCLC中的临床疗效。效益与ROS1重排类型无关（Shaw等人，2014年）。
ROS1 is a receptor tyrosine kinase that frequently forms gene fusions in several cancer types. Approximately 2% of NSCLC patients harbor a ROS1 gene fusion. Several fusion partners have been described with a constant ROS1-breakpoint, maintaining the kinase domain (Solomon B, 2015). Following case-studies and retrospective analyses, an expansion cohort of a phase-1 study showed clinical benefit of crizotinib in ROS1 rearranged NSCLC. The benefit was independent of the type of ROS1-rearrangement (Shaw et. al.,2014).